Dyne Therapeutics (DYN) PT Lowered to $45 at Morgan Stanley

July 31, 2026 8:00 AM

Morgan Stanley analyst Michael E Ulz lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $45.00 (from $47.00) while maintaining a Overweight rating.

No results found